• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Biomedical and Pharmaceutical Sciences
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 8 (2025)
Volume Volume 7 (2024)
Volume Volume 6 (2023)
Volume Volume 5 (2022)
Volume Volume 4 (2021)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 3 (2020)
Volume Volume 2 (2019)
Volume Volume 1 (2018)
elbadawy, H., Aljuhani, N. (2021). Gene silencing approaches for the treatment of hepatitis C virus infection. Journal of Advanced Biomedical and Pharmaceutical Sciences, 4(1), 42-44. doi: 10.21608/jabps.2020.49330.1108
hossein elbadawy; Naif Aljuhani. "Gene silencing approaches for the treatment of hepatitis C virus infection". Journal of Advanced Biomedical and Pharmaceutical Sciences, 4, 1, 2021, 42-44. doi: 10.21608/jabps.2020.49330.1108
elbadawy, H., Aljuhani, N. (2021). 'Gene silencing approaches for the treatment of hepatitis C virus infection', Journal of Advanced Biomedical and Pharmaceutical Sciences, 4(1), pp. 42-44. doi: 10.21608/jabps.2020.49330.1108
elbadawy, H., Aljuhani, N. Gene silencing approaches for the treatment of hepatitis C virus infection. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2021; 4(1): 42-44. doi: 10.21608/jabps.2020.49330.1108

Gene silencing approaches for the treatment of hepatitis C virus infection

Article 7, Volume 4, Issue 1, January 2021, Page 42-44  XML PDF (284.62 K)
Document Type: Original Article
DOI: 10.21608/jabps.2020.49330.1108
View on SCiNiTO View on SCiNiTO
Authors
hossein elbadawy email orcid ; Naif Aljuhani
College of Pharmacy, Taibah University Universities road, Madinah, Kingdom of Saudi Arabia
Abstract
Hepatitis C virus (HCV) infection is a worldwide concern. Only minor portion of the ‎infected patients can clear the virus whereas the majority (more than 70%) progress to ‎advanced stages of liver deterioration which in most cases lead to liver cirrhosis and ‎cancers if remained untreated. Current standard treatment for hepatitis C is the ‎combination treatment with polyethylene glycol pegylated interferon-α and ribavirin ‎‎(PEG-IFN-α/RBV). Conventional treatment for hepatitis is reported to show variable ‎degree of success and, most recently, the combination of two or more agents has shown ‎great promise. Conventional therapy for HCV, however, is time consuming and expensive ‎and could considerably reduce the quality of life for most of the patients. Gene therapy is ‎an emerging branch of science aimed at the manipulation of genetic sequences. Gene ‎therapy has been recently introduced to virology as a novel anti-viral class of medicines. ‎The innovative idea is to target the HCV viral genome by clipping or blocking to arrest ‎the viral replication. This can be achieved by gene silencing techniques such as siRNA. ‎This will cause viral degradation by hindering the viral genome functionality pre- or post-‎translational to offer a specific and promising tool which has not been investigated ‎thoroughly. Results from using siRNA in vitro are promising, however, this area of ‎research is still evolving.‎
Keywords
siRNA; RNAi; HCV; gene silencing
Main Subjects
Microbiology
Statistics
Article View: 315
PDF Download: 541
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.